11.07.2015 Views

biomedical sciences research institute - Research - University of Ulster

biomedical sciences research institute - Research - University of Ulster

biomedical sciences research institute - Research - University of Ulster

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

and Chief Scientific Officer/Director <strong>of</strong> Diabetica Limited.Main <strong>Research</strong> interests:• Insulin secretion• pancreatic islet cell function and demise• antidiabetic drugs• gene therapy• brain and gut peptides• glucose homeostasis• insulinoma and obesity.Esteem:2007 Hodgkin Award presented at the Annual Pr<strong>of</strong>essional Congress <strong>of</strong> Diabetes UKCommittees:Member <strong>of</strong> Diabetes UK Advisory CouncilMember <strong>of</strong> Diabetes UK <strong>Research</strong> CommitteeMember <strong>of</strong> Diabetes UK <strong>Research</strong> Advisory GroupMember <strong>of</strong> Diabetes UK Pr<strong>of</strong>essional Advisory CouncilMember <strong>of</strong> Diabetes UK Science and <strong>Research</strong> CommitteeFounding Chairman European Association for Study <strong>of</strong> Diabetes (EASD) Islet Study GroupFounding Member <strong>of</strong> Islet <strong>Research</strong> European and Latin American NetworksMember <strong>of</strong> Executive <strong>of</strong> IRELAN Alfa NetworkChairman, scientific sessions at Diabetes UK, EASD and other International meetingsConsultant to Shering PloughInvited LecturesSeminar on Novel Approaches to Diabetes Therapy, Takeda Pharmaceuticals, Amsterdam, 2007Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) Seminar Series Guest Lecture , Oxford, 2007Seminar on GIP Therapeutics and Diabetes, Boehringer Ingelheim Pharmaceutical Company, Biberach, Germany, 2007International Conference on Treatment and Prevention <strong>of</strong> Obesity, Copenhagen, 2007Seminar on Incretin Hormones and Diabetes, Organon Pharmaceutical Company, Oss, Netherlands, 2007Seminar on Therapeutic Gut Hormones, Novo Nordisk Ltd, Copenhagen, 2007Conference on New Approaches to Diabetes, Ipsen Pharmaceutical Company, Barcelona, 2007International Conference on Diabetes in Crisis, Dublin, 2007Diabetes UK Annual Pr<strong>of</strong>essional Congress, Dorothy Hodgkin Lecture, Glasgow, 2008Diabetes UK Annual Pr<strong>of</strong>essional Congress, Meet the Pr<strong>of</strong>essor, Glasgow, 2008International Conference on Importance <strong>of</strong> Early Phase Insulin Release in Type 2 Diabetes, Tokyo, 2008International Conference on Diabetes Mellitus and Obesity, Taif, Saudi Arabia, 2008FEND (Federation <strong>of</strong> European Nurses in Diabetes) 13th Annual Conference, Rome, September, 2008Royal Society <strong>of</strong> Medicine Conference on From Bench to Patient: taking Diabetes into the 21st Century, London,October, 2008Publications:Abdel-Wahab YHA, Marenah L, Flatt PR and Conlon JM; Insulin-releasing properties <strong>of</strong> the temporin family <strong>of</strong>antimicrobial peptides; Protein Pept. Letts, 14: 702-707, 2007Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O’Harte FPM and Flatt PR; Effects <strong>of</strong> antidiabetic drugson dipeptidyl peptidase IV activity: Nateglinide is an inhibitor <strong>of</strong> DPP IV and augments the antidiabetic activity <strong>of</strong>glucagon-like peptide-1; European Journal <strong>of</strong> Pharmacology, 568: 278-286, 200743

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!